Study on immunity of dengue virus and dengue vaccine development

Abstract

In the study of vaccines for dengue viruses, which are multivalent immunization, genetically and antigenically distinct, we should have more sophisticated understanding of viral immune physiology. Because the immune response to dengue and its role in the pathophysiology of dengue fever and dengue hemorrhagic fever are multifaceted, several different efforts have been made to engineer a protective vaccine. Because of space limitations, this review is focused only on vaccines that have emerged from preclinical studies into clinical trial.

Keywords

dengue fever / immunology / T cells / vaccines

References

[1] Durbin A P, Karron R A, Sun W, Vaughn D W, Reynolds M J, Perreault J R, Thumar B, Men R, Lai C J, Elkins W R, Chanock R M, Murphy B R, Whitehead S S (2001). Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3’-untranslated region. Am J Trop Med Hyg, 65: 405-413

[2] Durbin A P, Whitehead S S, McArthur J, Perreault J R (2005). rDEN4▵30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis, 191: 710-718

[3] Edelman R (2007). Dengue vaccines approach the finish line. Clin Infect Dis, 45 (Suppl 1): S56-60

[4] Halstead S B (2007). Dengue. Lancet, 370(9599): 1644-1652

[5] Hatch S, Mathew A, Rothman A (2008). Dengue vaccine: opportunities and challenges. IDRUGS, 11(1): 42-45

[6] Holman D H, Wang D, Raviprakash K, Raja N U, Luo M, Zhang J, Porter K R, Dong J Y (2007). Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol, 14(2): 182-189

[7] Kaufman B M, Summers P L, Dubois D R, Cohen W H, Gentry M K, Timchak R L, Burke D S, Eckels K H (1989). Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg, 41(5): 576-580

[8] Kautner I, Robinson M J, Kuhnle U (1997). Dengue virus infection: Epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention. J Pediatr, 131(4): 516-524

[9] Kliks S C, Nisalak A, Brandt W E, Wahl L, Burke D S (1989). Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg, 40: 444-451

[10] Kurane I, Brinton M A, Samson A L, Ennis F A (1991). Dengue virus-specific, human CD4⁺, CD8^-cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol, 65(4): 1823-1828

[11] Lai C Y, Tsai W Y, Lin S R, Kao C L, Hu H P, King C C, Wu H C, Chang G J, Wang W K (2008). Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol, 82(13): 6631-6643

[12] Livingston P G, Kurane I, Lai C J, Bray M, Ennis F A (1994). Recognition of envelope protein by dengue virus serotype-specific human CD4⁺, CD8^-cytotoxic T-cell clones. J Virol, 68(5): 3283-3288

[13] Monath T P (2007). Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med, 357(22): 2222-2225

[14] Rothman AL (2004). Dengue: defining protective versus pathologic immunity. J Clin Invest, 113: 946-951

[15] Shekhar C (2007). Deadly Dengue: New Vaccines Promise to Tackle This Escalating Global Menace. Chem Biol, 14(8): 871-872

[16] Sun W, Edelman R, Kanesa-Thasan N, Eckels K H, Putnak J R, King A D, Houng H S, Tang D, Scherer J M, Hoke C H Jr, Innis B L (2003). Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg, 69(6 Suppl): 24-31

[17] Whitehead SS, Blaney J E, Durbin A P, Murphy B R (2007). Prospects for a dengue virus vaccine. Nat Rev Microbiol, 5(7): 518-528

[18] Wilder-Smith A, Deen J L (2008). Dengue vaccines for travelers. Expert Rev Vaccines, 7(5): 569-578

[19] Young P R, Hilditch P A, Bletchly C, Halloran W (2000). An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol, 38(3): 1053-1057

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg